This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Efficacy and Safety of Budesonide Foam for Patients With Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis

This study has been completed.
Information provided by (Responsible Party):
Valeant Pharmaceuticals International, Inc. Identifier:
First received: November 4, 2009
Last updated: May 17, 2013
Last verified: November 2012
The purpose of this study is to establish the efficacy profile of rectally administered budesonide foam administered as 2mg/25mL BID for 2 weeks followed by 2mg/25mL QD for 4 weeks, as compared to an equivalent volume of rectally administered placebo foam over the same dosing schedule, in subjects who present with a diagnosis of active, mild to moderate, ulcerative proctitis (UP) or ulcerative proctosigmoiditis (UPS). During the study, eligible subjects will be allowed to maintain previously established oral 5-ASA treatment at doses up to 4.8g/day.

Condition Intervention Phase
Proctitis Proctosigmoiditis Drug: Budesonide Drug: Placebo Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Budesonide Foam Versus Placebo in Subjects With Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis

Resource links provided by NLM:

Further study details as provided by Valeant Pharmaceuticals International, Inc.:

Primary Outcome Measures:
  • The proportion of subjects who achieve remission. [ Time Frame: 6 weeks ]

Enrollment: 281
Study Start Date: November 2009
Primary Completion Date: March 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Budesonide
Budesonide rectal foam
Drug: Budesonide
2mg/25mL BID for 2 weeks followed by 2mg/25mL QD for 4 weeks
Placebo Comparator: Placebo
Placebo foam
Drug: Placebo
Placebo foam/25mL BID for 2 weeks followed by 2mg/25mL QD for 4 weeks

Detailed Description:

This is a Phase 3, randomized, double-blind, placebo-controlled, multi-center study to assess the efficacy and safety of budesonide foam in subjects with active mild to moderate proctitis or proctosigmoiditis. Approximately 430 subjects will be enrolled into the study and receive either placebo foam or budesonide foam twice a day for 2 weeks followed by once a day for 4 weeks. Participation in the study will last approximately 11 weeks, depending on the timing of study visits.

During the study, eligible subjects will be allowed to maintain previously established oral 5-ASA treatment at doses up to 4.8g/day. Periodic safety monitoring, including physical examinations, vitals, laboratory testing, and recording of AEs and concomitant medications, will be performed during the study


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Voluntarily sign written informed consent.
  • Male or non-pregnant and non-lactating females ≥18 years of age.
  • Confirmed diagnosis (by endoscopy procedure) of active, mild to moderate ulcerative proctitis or proctosigmoiditis extending no further than 40cm from the anal verge.
  • Must possess a baseline MMDAI score between 5 and 10.
  • Visible blood in stool.

Exclusion Criteria:

  • History or current diagnosis of Crohn's disease and indeterminate colitis.
  • Prior gastrointestinal surgery except appendectomy and hernia.
  • Concomitant active gastrointestinal disease or distortion of intestinal anatomy.
  • History of diverticulitis, collagenous colitis, celiac disease, recurrent pancreatic or known gallbladder disease.
  • Uncontrolled, previously diagnosed type 1 or 2 diabetes mellitus.
  • Uncontrolled abnormal thyroid function.
  • Unstable significant cardiovascular, endocrine, neurologic or pulmonary disease.
  • Hemoglobin levels < 7.5 g/dL.
  • History of sclerosing cholangitis, cirrhosis, or hepatic impairment.
  • Renal disease manifested by > 2.0mg/dL serum creatinine.
  • History of avascular hip necrosis, active tuberculosis, ocular herpes simplex or ocular varicella zoster, malignant disease, and HIV or hepatitis B or C.
  • Adrenal insufficiency.
  • Active systemic or cutaneous infection or toxic megacolon, fistula, perforation or abscess.
  • History of uncontrolled psychiatric disorders or seizure disorders.
  • History of asthma requiring ongoing use of inhaled steroids.
  • Recent history of drug or alcohol abuse.
  • Positive stool test for bacterial pathogens, C diff or O&P.
  • Vaccination within 28 days prior to Randomization.
  • Allergies to budesonide or to any other items used in its preparation.
  • Participation in another clinical trial in the past 30 days.
  • Pregnant or at risk of pregnancy.
  • Taking a prohibited medication. Some medications to treat UP/UPS are prohibited during participation in the study, including laxatives and anti-diarrhea medications; however, oral 5-ASA agents at doses up to 4.8g/day and daily fiber supplements are allowed. Other medications (e.g., antibiotics, anti-seizure and anti-coagulant medicines) are also prohibited.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01008423

  Hide Study Locations
United States, Alabama
Dothan, Alabama, United States
United States, Arizona
Mesa, Arizona, United States
Tucson, Arizona, United States
United States, Arkansas
Little Rock, Arkansas, United States
United States, California
Chula Vista, California, United States
Garden Grove, California, United States
Mission Hills, California, United States
Monterey, California, United States
Roseville, California, United States
San Francisco, California, United States
United States, Colorado
Lafayette, Colorado, United States
United States, Connecticut
Bristol, Connecticut, United States
Hamden, Connecticut, United States
United States, Florida
Altamonte Springs, Florida, United States
Cape Coral, Florida, United States
Hialeah, Florida, United States
North Miami Beach, Florida, United States
Winter Park, Florida, United States
United States, Georgia
Macon, Georgia, United States
Marietta, Georgia, United States
Suwanee, Georgia, United States
United States, Illinois
Molina, Illinois, United States
United States, Iowa
Davenport, Iowa, United States
United States, Kansas
Topeka, Kansas, United States
United States, Louisiana
Metairie, Louisiana, United States
United States, Maryland
Annapolis, Maryland, United States
Hagerstown, Maryland, United States
Prince Frederick, Maryland, United States
Silver Springs, Maryland, United States
United States, Michigan
Chesterfield, Michigan, United States
Rochester, Michigan, United States
United States, Mississippi
Tupelo, Mississippi, United States
United States, Missouri
St. Louis, Missouri, United States
United States, New Jersey
Egg Harbor Twp., New Jersey, United States
Marlton, New Jersey, United States
United States, New York
Great Neck, New York, United States
Mineola, New York, United States
New York, New York, United States
North Massapequa, New York, United States
Stony Brook, New York, United States
United States, North Carolina
Asheville, North Carolina, United States
Fayetteville, North Carolina, United States
Greensboro, North Carolina, United States
Jacksonville, North Carolina, United States
New Bern, North Carolina, United States
Raleigh, North Carolina, United States
Rocky Mount, North Carolina, United States
Wilmington, North Carolina, United States
United States, Ohio
Beachwood, Ohio, United States
United States, Oklahoma
Tulsa, Oklahoma, United States
United States, Oregon
Portland, Oregon, United States
United States, Tennessee
Germantown, Tennessee, United States
United States, Texas
Houston, Texas, United States
LaPorte, Texas, United States
Pasedena, Texas, United States
Plano, Texas, United States
San Antonio, Texas, United States
United States, Utah
Ogden, Utah, United States
West Valley City, Utah, United States
United States, Virginia
Chesapeake, Virginia, United States
Lynchburg, Virginia, United States
United States, Wisconsin
Monroe, Wisconsin, United States
Sponsors and Collaborators
Valeant Pharmaceuticals International, Inc.
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Valeant Pharmaceuticals International, Inc. Identifier: NCT01008423     History of Changes
Other Study ID Numbers: BUCF3002
Study First Received: November 4, 2009
Last Updated: May 17, 2013

Keywords provided by Valeant Pharmaceuticals International, Inc.:
Budesonide foam
Additional relevant MeSH terms:
Colitis, Ulcerative
Gastrointestinal Diseases
Digestive System Diseases
Rectal Diseases
Intestinal Diseases
Colonic Diseases
Sigmoid Diseases
Pathologic Processes
Inflammatory Bowel Diseases
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Pharmacologic Actions

Additional relevant MeSH terms:
Pathologic Processes
Gastrointestinal Diseases
Digestive System Diseases
Rectal Diseases
Intestinal Diseases
Colonic Diseases
Sigmoid Diseases
Peripheral Nervous System Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Anti-Inflammatory Agents
Bronchodilator Agents
Autonomic Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Hormones processed this record on September 21, 2017